Member Info for 1pencil

S4 has a lot of movers and shakers onboard, would be surprised if talks even at low levels are not already being aired.

The pivot has commenced, albeit a tad rocky thanks to Feds meeting notes.

"HSBC announced cuts beginning Thursday on its residential mortgage interest rates, with several falling below 5% for the first time since April 2023. The largest drop was to its 10-year fixed rate remortgage deals, one of which is down from 4.99% to 3.99%"

.https://www.cnbc.com/2024/01/04/uk-mortgage-rates-are-finally-falling-as-homeowners-hope-for-relief.html

Got to be on someone's radar:

FTSE private takeovers will continue 'unless action is taken', analysts warn

The 'relentless' pace of delisting and takeovers by foreign buyers will continue if urgent action to incentivise UK stock ownership is not taken, a senior analyst has warned.

https://www.thisismoney.co.uk/money/markets/article-12921859/FTSE-private-takeovers-continue-unless-action-taken-analysts-warn.html?ito=email_share_article-top

Its not just one year in isolation tho', Check links below but average for one of the hedge funds quoted was 7% before fees.

Investors automatically think 'hedge fund' it makes money, that's how they have been conditioned to thinking by the media and probably the hedge funds themselves lol

FTSE private takeovers will continue 'unless action is taken', analysts warn

The 'relentless' pace of delisting and takeovers by foreign buyers will continue if urgent action to incentivise UK stock ownership is not taken, a senior analyst has warned.

https://www.thisismoney.co.uk/money/markets/article-12921859/FTSE-private-takeovers-continue-unless-action-taken-analysts-warn.html?ito=email_share_article-top

"The company witnessed impressive results from the Swedish Match business in the third quarter, driven by ZYN in the United States. Revenues from smoke-free products (excluding Wellness and Healthcare) jumped 35.7% to $3,234 million (up 16.2% organically) in the third quarter of 2023"

https://finance.yahoo.com/news/philip-morris-pm-focus-smoke-124600110.html

This is the joint presentation from Jan 22 with Wilbur Ellis

From 20.00 minutes in talk is more Pretec focused although the whole video is good to look back on now registrations are coming through.

https://www.investormeetcompany.com/meetings/wilbur-ellis-and-plant-health-care-discuss-us-market-opportunities

Qube have a constantly poor record, happy to have them onboard.

That's incorrect, see posts on both Qube and Systematica both of which have suffered another poor year underperforming the S & P (again)

"The potential Bulls are more than happy to let the Bears do the work right now ...... and with the Red Sea issue causing inflation concerns on higher costs for moving goods around .... the Bears are winning in the markets ...overall"

Wilbur Ellis would probably market TEIKKO once US approval is granted, seem to remember during joint IMC presentation they were keen on nematicide technology as part of an overall solution, TEIKKO has good compatibility with most other products combined with long shelf life (no concerns about over stocking).

Notifications relate to SEC which are often delayed

Haven't totalled up the sales but it looks meaningful, one would hope anyone that wanted out is now out.

https://fintel.io/so/gb/sfor

It looks as though Fidelity sold out month or so back across many of their funds, no doubt much of this stock went straight to Capital Group/Patient Capital effectively cancelling one another out.

Relevant notifications for the latter should trickle through soon.

Think you're on the money there AS, this mornings RNS confused/spooked which helped the rug pulling exercise along with a few negative posts, all helps to cause the jitters.

Imagine you're a prop trader reading this thread what would you have done, go short, take it down hard my guess.

Fair credit as they have done a pretty good job at sowing the seeds (excise the pun) ahead of formal approval, coverage in the trade magazines has been good too.

Sounded confident on approving a distributor soon for this years growing season, that would be welcome given US overstocking issues.

Still no change, whatever is happening to Heinz it must be pretty big to suspend their global web site presence over Crimbo.

You would think shoppers would be all over social media but not a sausage!

All we really know is there has been a shift towards commercialisation and shareholder interests, if this includes a takeover while keeping their long term goals intact then possible.

Given the figures involving Takeda deal, you have to wonder if this topic has not already surfaced before.

"And that reason is very simple to understand. Even though the Brazilian market has a 70% share of biological products in the management of nematodes, some precautions in their application in the field still need attention, such as storage and transport temperature, shelf life, compatibility with other products and influence of environmental conditions after their application.

PHC68949 (TEIKKO) is a peptide with a unique mode of action, based on PREtec – Plant Response Elicitor Technology and brings benefits in nematode management, such as ease of storage, three years of shelf life, compatibility with other products, including fungicides, ease of use in seed treatment and consistent efficiency in different environmental conditions."

https://www.linkedin.com/posts/plant-health-care-brasil_phc68949-the-only-bionematicide-that-protects-activity-7146490086690402304-9ZcE?utm_source=share&utm_medium=member_desktop

Those that successfully pushed for a change in strategy will no doubt be monitoring all of this M & A activity.

Posted this yesterday on S4 thread, it adds background to the earlier Qube figures.

Barclays often quote Systematica Bluet Trend as being one of the top three quant/Ai type hedge funds.

___________________________________________________

Systematica underperforms S & P (again) 27 Dec 2023 20:27

Another dreadful year for their flagship fund

BLUETREND FUND LTD. SYSTEMATICA INVESTMENTS

https://www.rcmalternatives.com/fund/bluetrend-fund-ltd-systematica-investments/

Over the holiday break, in the US, Bristol Myers Squibb scooped up Boston innovator Karuna Therapeutics for £11.5billion.

Britain’s Astra deepened its commitment to oncology and China with the purchase of Gracell for just under £1billion.

Earlier in December, Astra splashed a similar amount on Seattle-based Icosavax which is pursuing a vaccine for RSV, a respiratory virus.

Pfizer, after a regulatory pause, has just secured approval for its £33billion takeover of cancer care group Seagen as it plays catch-up with Astra and others.

https://www.thisismoney.co.uk/money/comment/article-12904577/ALEX-BRUMMER-Big-pharma-bets-biotech-global-drugs-industry-booms.html